Experience

Lucid Health Consulting - Experience Matters.

• Australia
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Director and Partner

  • Nov 2015 - Present

  Lucid Health Consulting was founded in 2016 by the three directors, George Papadopoulos, Michael Aristides and Steve Crowley, each with over 25 years experience across the areas of health economics and market access. The directors are supported by an extended team with a proven track record in medical writing, biostatistics, economic modelling and medical information. The strength of Lucid Health Consulting is demonstrated by the quote from Aristotle, “the whole is greater than the sum of its parts”. By joining forces, the directors of Lucid Health Consulting each contribute their expertise to a project, resulting in a more comprehensive and ultimately more successful outcome. The directors maintain a ‘hands-on’ approach, leading every project and acting as the key point of contact to provide seamless project management. We truly believe that “Experience Matters”..Lucid Health Consulting provides expertise in health economics, health technology assessments, pricing and reimbursement strategy. LHC provides clients with comprehensive HTA packages and submissions along with in depth commercial and reimbursement feasibility assessments. Lucid Health Consulting has prepared submissions for a range of advisory committees including PBAC, MSAC, PHARMAC, SMC, NICE and support packages in other European countries and Asia Pacific. Lucid Health Consulting has worked across a range of therapeutic areas including oncology, cardiovascular, CNS, Infectious Diseases and Immunology.contact: info@lucidhealthcon.com



IMS Health

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Principal HEOR, IMS Health London

  • May 2005 - Feb 2008

  This senior UK based role was a combination of HEOR consulting across international (and some local) projects, business development and thought leadership. The focus for the HEOR was on global and regional projects; cost-effectiveness models, systematic reviews and PRO studies. In addition, the patient data resources at IMS were used to enhance the HEOR projects, my experience was in the primary care and Oncology data. This senior UK based role was a combination of HEOR consulting across international (and some local) projects, business development and thought leadership. The focus for the HEOR was on global and regional projects; cost-effectiveness models, systematic reviews and PRO studies. In addition, the patient data resources at IMS were used to enhance the HEOR projects, my experience was in the primary care and Oncology data.



M-TAG Sydney & M-TAG London

• Director and co-founder

  • Mar 1995 - May 2005

  M-TAG was a front running consultancy in health economics and health technology assessment. It was the premier company in Australia and expanded into the European market via a UK office (headed by myself) since 2000 when the mandatory requirements commenced via NICE. M-TAG was a multi-disciplinary group providing submissions for reimbursement to the PBAC, conducting pharmaco-economic research, market research for the pharmaceutical industry, database management and statistical analysis. M-TAG was a front running consultancy in health economics and health technology assessment. It was the premier company in Australia and expanded into the European market via a UK office (headed by myself) since 2000 when the mandatory requirements commenced via NICE. M-TAG was a multi-disciplinary group providing submissions for reimbursement to the PBAC, conducting pharmaco-economic research, market research for the pharmaceutical industry, database management and statistical analysis.